Screening for Conditions by Electronic Nose Technology (SCENT III) (Clinical Trial Not Allowed)
ID: 360672Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360672
Timeline
    Description

    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "Screening for Conditions by Electronic Nose Technology (SCENT III)," aimed at developing innovative electronic nose technologies for disease diagnosis and monitoring. This initiative seeks to enhance noninvasive diagnostic platforms that utilize volatile organic compound (VOC) signatures from human skin, thereby improving the detection and analysis of various diseases in everyday settings. The project aligns with the NIH's goal of accelerating the translation of scientific knowledge into effective treatments, with an estimated award date of April 5, 2027, and a project start date on the same day. Interested applicants can reach out to Leah Croucher, PhD, at leah.croucher@nih.gov or by phone at 240-701-2580 for further information.

    Point(s) of Contact
    Leah Croucher, PhD
    (240) 701-2580
    leah.croucher@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Transformative Non-Invasive/Minimally Invasive Technologies for Imaging the Olfactory System Across Scales (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "Transformative Non-Invasive/Minimally Invasive Technologies for Imaging the Olfactory System Across Scales (R01 Clinical Trial Optional)." This initiative aims to solicit research applications focused on developing advanced non-invasive and minimally invasive imaging technologies to visualize the human olfactory system, addressing the current limitations in imaging techniques that hinder understanding of olfactory disorders. The opportunity emphasizes the need for multimodal approaches and encourages collaborations among experts in various fields such as olfaction, biomedical imaging, and bioengineering. Interested applicants should note that applications are not currently being solicited, but they can prepare for submission as the estimated synopsis post date is October 27, 2025, with a closing date of November 27, 2025. For further inquiries, potential applicants can contact Dr. Merav Sabri at merav.sabri@nih.gov or by phone at 301-827-5992.
    Mechanisms Underlying Olfactory Dysfunction in Aging and Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) aimed at investigating the mechanisms underlying olfactory dysfunction in aging, Alzheimer’s disease (AD), and Alzheimer’s disease-related dementias (ADRD). This initiative seeks to explore the relationship between olfactory decline and various health outcomes in older adults, potentially identifying novel therapeutic targets for disease modification. The research may involve studies on older adults and animal models, utilizing diverse methodologies such as cellular, molecular, and imaging techniques. While applications are not currently being solicited, interested researchers are encouraged to prepare collaborative projects in anticipation of the funding opportunity, which is expected to utilize the R01 activity code. For further inquiries, contact Coryse St. Hillaire-Clarke, Ph.D., at 301-496-9350 or via email at sthillaireclacn@mail.nih.gov. The estimated synopsis post date is August 6, 2026, with a closing date for applications anticipated on October 6, 2026, and awards expected to be made by July 6, 2027.
    Discovery of in vivo Chemical Probes for the Nervous System
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting the discovery of in vivo chemical probes for the nervous system, specifically targeting novel brain mechanisms. This initiative, led by the National Institute on Aging (NIA) in collaboration with the National Eye Institute (NEI), the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH), seeks applicants who possess validated starting compounds for chemical optimization and bioassays to explore new analog compounds. The focus will be on developing small molecules that can enhance understanding of biological processes relevant to brain diseases, with an emphasis on innovative biological targets. Interested applicants can reach out to Dr. Paul G. Grothaus at grothausp@mail.nih.gov or call 240-688-6634 for further information, with the estimated synopsis posting date set for February 26, 2026, and a projected award date of April 5, 2027.
    Opportunities for Collaborative Research at the NIH Clinical Center
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Opportunities for Collaborative Research at the NIH Clinical Center," aimed at supporting collaborative translational research projects that enhance the application of basic biological discoveries to clinical settings. This program encourages partnerships between NIH intramural investigators and extramural researchers to accelerate patient-centric translational research, focusing on understanding disease processes and developing new therapeutic interventions, diagnostics, or prevention strategies. Interested small businesses can apply for this cooperative agreement, with no cost-sharing requirement, and should note that the estimated synopsis post date is September 1, 2025, with a closing date of December 12, 2025. For further inquiries, applicants can contact Dr. David J. Eckstein at 301-496-4121 or via email at ClinicalCtrPartner@mail.nih.gov.
    NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming opportunity for a cooperative agreement focused on prospective observational or biomarker validation studies through the National Institute of Dental and Craniofacial Research (NIDCR). This initiative aims to solicit applications for studies that involve the prospective collection or continued analysis of data and biospecimens, with an emphasis on well-designed clinical studies that can enhance understanding and improve dental, oral, and craniofacial health. Such studies are crucial for assessing exposure and its relationship to disease development, as well as validating biomarkers for diagnosis and treatment response. While applications are not currently being accepted, interested investigators are encouraged to prepare collaborative proposals in anticipation of the opportunity, which is expected to be formally announced in November 2025, with a closing date for submissions in February 2026. For further inquiries, potential applicants can contact Dr. Lorena Baccaglini at lorena.baccaglini@nih.gov or by phone at 301-435-7908.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at advancing research in novel screening methods and therapeutic interventions for genetic conditions identified through newborn screening. This initiative encourages the development of innovative screening assays, the use of artificial intelligence, and the exploration of socio-economic implications related to newborn screening, with a focus on conditions that may benefit from early detection and treatment. The grant supports long-term research projects (R01) and is open to a diverse range of applicants, including higher education institutions and community-based organizations, with applications accepted until November 16, 2027. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-265.html.
    Addressing Health Inequities in Clinical Diagnostics (R43/R44 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Addressing Health Inequities in Clinical Diagnostics" under the Small Business Innovation Research (SBIR) program (R43/R44). This initiative invites Small Business Concerns (SBCs) to develop improved clinical diagnostics that address health disparities caused by existing clinical laboratory assays and point-of-care devices, particularly those that do not adequately consider diverse patient populations. The program aims to foster advancements that enhance health outcomes for historically underrepresented groups by encouraging applicants to identify specific disparities and propose innovative solutions. Applications will be accepted starting March 5, 2024, with a close date of January 5, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-158.html.
    Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development," aimed at supporting the development and validation of digital health technology-driven biomarkers and clinical outcome assessments for use in clinical trials. This initiative seeks to enhance the standardization of remote assessments and address unmet clinical needs across multiple diseases, requiring applicants to engage with non-profit patient advocacy organizations and evaluate technologies in diverse populations. The funding mechanism consists of two phases: the UG3 phase focuses on assessing the technical performance of proposed technologies, while the UH3 phase supports longitudinal clinical studies for validation. Interested applicants can find more information and application details at the NIH grants website, with a submission deadline of June 22, 2026, and no cost-sharing or matching requirement.
    NIH Blueprint for Neuroscience: Coordination Center for Interoception Research (BPCCIR) (U24, Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the establishment of the NIH Blueprint for Neuroscience Research Coordination Center for Interoception Research (BPCCIR) through a cooperative agreement (U24), with an estimated total program funding of $700,000. The primary objectives of this initiative include fostering a multidisciplinary team of interoception researchers, developing digital communication platforms for collaboration, organizing annual scientific meetings, and identifying challenges and opportunities in interoception research to enhance population health. This research is crucial for understanding internal bodily signals and their implications for health, particularly in relation to chronic diseases and mental health disorders. Interested applicants, including small businesses and other eligible entities, should note that the estimated synopsis close date is November 10, 2025, with an anticipated award date of July 1, 2026. For further inquiries, contact Wen Chen at 301-451-3989 or via email at chenw@mail.nih.gov.
    Promoting a Basic Understanding of Chemical Threats to Skin (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Promoting a Basic Understanding of Chemical Threats to Skin," aimed at small businesses interested in researching the pathological mechanisms of skin injuries caused by toxic chemicals. The initiative seeks to elucidate the commonalities in the mechanisms of skin injuries from various vesicants, such as sulfur mustard and Lewisite, with the goal of identifying shared therapeutic targets and developing broad-spectrum medical countermeasures for mass casualty events. The estimated total program funding is $2,500,000, with approximately five awards expected, and interested applicants are encouraged to collaborate and prepare their proposals ahead of the anticipated application period, which is expected to open in early 2026. For further inquiries, potential applicants can contact Dr. Peter J. Koch at Peter.Koch@NIH.gov or by phone at 240-987-8325.